Core Viewpoint - Catalyst Pharmaceuticals, Inc. is set to release its third quarter 2025 financial results on November 5, 2025, and will host a conference call and webcast on November 6, 2025, to discuss these results and provide a business update [1][2]. Group 1: Financial Results Announcement - The company will announce its third quarter 2025 financial results after market close on November 5, 2025 [1]. - A conference call and webcast will take place on November 6, 2025, at 8:30 AM ET to discuss the financial results [2]. Group 2: Conference Call & Webcast Details - The conference call can be accessed via US/Canada dial-in number 877-407-8912 and international dial-in number 201-689-8059 [3]. - The webcast will be available on the company's website and a replay will be accessible for at least 30 days following the event [3]. Group 3: Company Overview - Catalyst Pharmaceuticals is focused on developing and commercializing novel medicines for patients with rare diseases [4]. - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [4].

Core Insights - Rezolve AI is undergoing significant management changes aimed at enhancing operational execution, accelerating global revenue growth, and reinforcing its leadership in AI and digital commerce [1][7][8] Management Changes - Daniel M. Wagner, the Founder and CEO, emphasizes that the new leadership appointments are designed for scale, discipline, and innovation, positioning the company for growth [2] - Arthur Yao has been appointed as Chief Operating and Financial Officer (COFO), overseeing both operations and finance globally, focusing on efficiency and profitability [2] - Richard Burchill continues as Group Finance Director, ensuring financial performance and integrity as the company expands [3] Sales and Growth Strategy - Crispin Lowery has been appointed Chief Revenue Officer (CRO), tasked with building a global sales organization and driving revenue acceleration through a unified go-to-market structure [4] - Roland Gossage transitions to Chief Growth Officer (CGO), focusing on aligning product development with market opportunities to enhance commercial success [5] Technology and Innovation - Salman Ahmed has been named Chief Scientist, leading the AI Lab and establishing the AI Academy to advance proprietary research and applied AI capabilities [6] - Collaboration with Sauvik Banerjjee, Chief Digital Officer, aims to unify AI, technology, and digital operations for seamless innovation deployment [6] Strategic Positioning - The leadership changes come at a time of momentum for Rezolve AI, following strategic acquisitions that have enhanced its data and payments infrastructure [7] - The strengthened leadership team is expected to facilitate Rezolve's evolution into a globally scaled, AI-powered commerce platform [7][8]

Core Insights - UniFirst Corporation reported its fourth quarter and full year financial results for fiscal 2025, highlighting a solid performance despite the absence of an extra operational week compared to the previous fiscal year [1][4]. Financial Highlights - Q4 2025 revenues were $614.4 million, down from $639.9 million in Q4 2024, but increased by 3.4% when excluding the impact of the extra week in the prior year [6][11]. - Full year revenues for fiscal 2025 reached $2.432 billion, a slight increase of 0.2%, with a 2.1% increase when excluding the extra week [6][11]. - Operating income for Q4 2025 was $49.6 million, compared to $54.0 million in Q4 2024, while full year operating income was $184.5 million, up 0.5% from the previous year [6][11]. - Net income for Q4 2025 was $41.0 million, down from $44.6 million in Q4 2024, while full year net income increased to $148.3 million from $145.5 million [6][11]. Segment Performance - The Uniform & Facility Service Solutions segment reported Q4 revenues of $560.1 million, a decrease from $586.0 million in the prior year, with organic growth of 2.9% attributed to new account sales and improved customer retention [6][11]. - The First Aid & Safety Solutions segment saw revenues of $31.1 million in Q4 2025, up from $29.3 million in Q4 2024, reflecting a strong organic growth of 12.4% [12]. - Adjusted EBITDA margin for the Uniform & Facility Service Solutions segment was 14.3% in Q4 2025, down from 14.9% in Q4 2024, impacted by investments in growth and digital transformation [6][8]. Cost and Investment Insights - Costs related to Key Initiatives, including CRM and ERP projects, amounted to $1.4 million in Q4 2025 and $6.8 million for the full year, affecting operating and Adjusted EBITDA margins [3][4][7]. - The company anticipates $7.0 million in costs related to Key Initiatives for fiscal 2026 [10]. Balance Sheet and Cash Flow - As of August 30, 2025, cash and cash equivalents totaled $203.5 million, an increase from $161.6 million in the prior year [12][17]. - Cash flow from operating activities increased to $296.9 million in fiscal 2025, reflecting a 0.5% growth [12][22]. - The company repurchased 402,415 shares for approximately $70.9 million during fiscal 2025, with $40.6 million remaining under its share repurchase authorization [12][22]. Future Outlook - For fiscal 2026, UniFirst expects revenues between $2.475 billion and $2.495 billion, with fully diluted earnings per share projected between $6.58 and $6.98 [10][12].

Strategic joint acquisition supports sustainable supply chain for execution of key industry players’ backlogWINNIPEG, Manitoba, Oct. 22, 2025 (GLOBE NEWSWIRE) -- NFI Group Inc. (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) and GILLIG LLC, today announced that the companies have formed a 50/50 joint venture that acquired the assets of American Seating Inc., a producer of seats for transit, motorcoach, and rail applications. The joint acquisition by the two U.S. heavy-duty transit bus manufacturers secures a critical c ...

Atlanta, GA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI), a developer of advanced AI-powered security screening and imaging systems, today announced the successful delivery of its SENTINEL® Fixed-Gantry CT Scanner to the Virginia Department of Corrections as part of a pilot to support development of a customized contraband detection algorithm for correctional facility screening operations. This delivery marks a significant milestone in ScanTech ...

Core Insights - Kyverna Therapeutics, Inc. is set to host a conference call on October 29, 2025, to discuss interim data from the KYSA-6 Phase 2 clinical trial of KYV-101 for generalized myasthenia gravis [1] - The data will also be presented at the AANEM Annual Meeting in San Francisco from October 29 to November 1, 2025 [1] Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases, with its lead candidate, KYV-101, in late-stage clinical development [5] - The company is conducting registrational trials for stiff person syndrome and myasthenia gravis, along with ongoing multi-center Phase 1/2 trials for lupus nephritis [5] - Kyverna is also exploring other indications such as multiple sclerosis and rheumatoid arthritis through various trials [5] Product Details - KYV-101 is a fully human, autologous CD19 CAR T-cell therapy designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset [4] - The therapy has the potential to provide durable drug-free, disease-free remission in autoimmune diseases with a single administration [4]

Core Insights - Equillium, Inc. is hosting a virtual key opinion leader event on November 5, 2025, focusing on the unmet needs and treatment landscape in ulcerative colitis, particularly the potential of Aryl Hydrocarbon Receptor (AhR) modulation [1][2] Company Overview - Equillium is a clinical-stage biotechnology company specializing in developing novel therapeutics for severe autoimmune and inflammatory disorders with high unmet medical needs [5] - The company's pipeline includes several novel immunomodulatory assets targeting immuno-inflammatory pathways [5] Event Details - The event will feature experts Francisco J. Quintana, PhD, and Brian Feagan, MD, discussing the evolving treatment landscape in ulcerative colitis and the promise of AhR targeting [2] - Company management will present a scientific overview of EQ504, an oral, colon-targeted AhR modulator, and its preclinical data demonstrating its mechanism of action [3] - A live Q&A session will follow the presentations, and a replay will be available on Equillium's website [4]

SCOTTSDALE, Ariz., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, Inc. (Nasdaq: BRCB) (“Black Rock Coffee Bar”) today announced that the Company plans to host a conference call to discuss its third quarter 2025 financial results on November 11th, 2025, at 5:00 p.m. Eastern Time. The conference call can be accessed live over the phone by dialing 1-877-704-4453 or for international callers, 1-201-389-0920. A live webcast of the conference call will also be available in the investor relations section ...

Core Insights - Calidi Biotherapeutics, Inc. has formed a Scientific Advisory Board (SAB) to enhance the development of its RedTail platform and advance its lead candidate CLD-401 into clinical trials [1][2][4] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted genetic medicines using its proprietary RedTail platform, which employs an engineered enveloped oncolytic virus for systemic delivery to metastatic sites [18][19] Scientific Advisory Board Formation - The SAB consists of leading industry and academic researchers with extensive experience in drug development, aimed at guiding the efficient development of CLD-401 [1][4] - Founding members include: - Mace L. Rothenberg, MD, with over 30 years in drug development and a history of leading clinical development at Pfizer [4][6] - Dmitriy Zamarin, MD, PhD, a leader in virotherapy for cancer and a member of the Icahn Genomics Institute [7][9] - John Wrangle, MD, MPH, an expert in IL-15-based treatment for metastatic cancer [10][12] - David T. Curiel, MD, PhD, recognized for his work in cancer immunotherapy and virotherapy [14][16] RedTail Platform and CLD-401 - The RedTail platform utilizes a genetically engineered vaccinia virus designed to overexpress CD55, allowing for targeted delivery of genetic medicine to disease sites while avoiding immune clearance [2][3] - CLD-401 is designed to target metastatic sites, replicate in tumor cells, and induce immune responses through the expression of IL-15 superagonist in the tumor microenvironment [3][19]

Renowned Menopause and Hormone Specialist to Help Guide and Represent LifeMD’s Comprehensive and Personalized Care Offering for WomenNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Tara Scott, MD, widely known as “The Hormone Guru,” as ambassador and clinical advisor for its comprehensive women’s health program. A respected physician, educator, and advocate, Dr. Scott will help champion LifeMD’s ...